STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

RGEN REPLIGEN CORPORATION StockScouter® Report

3

StockScouter® Score

REPLIGEN CORPORATION, a mid cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with slightly less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • One or more analysts has significantly increased quarterly earnings estimates for RGEN. Positive

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative
  • The ratio of RGEN’s forward price-to-earnings multiple to its estimated growth rate is well above the average of comparably-sized companies in the StockScouter universe. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 40% done.
Progress: 60% done.
Low
High

Core Model Grades

B
D
F
B

Previous Ratings

3
2
4